Erythropoetins in Therapy from the Point of View of a Medicinal Chemist

被引:0
|
作者
Farsa, Oldrich [1 ]
Zubac, Peter [1 ]
机构
[1] Univ Vet & Pharmaceut Sci Brno, Fac Pharm, Dept Chem Drugs, Palackeho 1946-1, Brno 61242, Czech Republic
来源
CHEMICKE LISTY | 2019年 / 113卷 / 09期
关键词
biological therapeutics; haematopoietic factors; erythropoietin; RECOMBINANT-HUMAN-ERYTHROPOIETIN; DARBEPOETIN;
D O I
暂无
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Hematopoietic growth factors are cytokines which stimulate growth of hematopoietic pluripotent stem cells and their differentiation and maturation into fully functional blood cells, either erythrocytes or various types of white blood cells. Erythropoietin is a glycosylated peptide hormone which stimulates production of red blood cells. It is used for treatment of anaemia caused by a chronic kidney failure. For therapeutic purposes, it is produced by recombinant technologies predominantly using modified mammalian cells. This procedure leads, however, to peptides of the same sequence of 165 amino acids but with different glycosylation patterns. These different mixtures of erythropoietin glycoforms have been designated with different INN names epoetin alfa - omega. Peginesatid (Omontys (R)) is a synthetic erythropoietin receptor agonist, the structure of which does not match that of erythropoietin. It is a pegylated covalent dimer of two identical peptide chains. It has been abandoned due to an increased mortality from cardiovascular reasons and due to dangerous allergies.
引用
收藏
页码:540 / 544
页数:5
相关论文
共 50 条
  • [1] nD QSAR:: a Medicinal Chemist's point of view
    Müller, G
    QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS, 2002, 21 (04): : 391 - 396
  • [2] Natural Compounds Promoting Weight Loss: Mechanistic Insights from the Point of View of the Medicinal Chemist
    Ribaudo, Giovanni
    Ongaro, Alberto
    Zagotto, Giuseppe
    NATURAL PRODUCTS JOURNAL, 2019, 9 (02): : 78 - 85
  • [3] Similarity and dissimilarity: A medicinal chemist's view
    Kubinyi, H
    PERSPECTIVES IN DRUG DISCOVERY AND DESIGN, 1998, 9-11 : 225 - 252
  • [4] DEVELOPMENT OF DRUG REQUIREMENT OF CENTRAL RESCUE AND INTENSIVE THERAPY UNIT FROM POINT OF VIEW OF CHEMIST
    MIRAM, R
    HUCKO, T
    DEUTSCHE GESUNDHEITSWESEN-ZEITSCHRIFT FUR KLINISCHE MEDIZIN, 1978, 33 (44): : 2085 - 2087
  • [5] Thermodynamic concepts: point of view of the chemist
    Lemarchand, Herve
    ACTUALITE CHIMIQUE, 2009, (329): : 36 - 41
  • [6] Beryllium-associated diseases from a chemist's point of view
    Buchner, Magnus R.
    ZEITSCHRIFT FUR NATURFORSCHUNG SECTION B-A JOURNAL OF CHEMICAL SCIENCES, 2020, 75 (05): : 405 - 412
  • [7] Progress in cannabis research from a pharmaceutical chemist's point of view
    Mueller, Christa E.
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2019, 62 (07) : 818 - 824
  • [8] Laser crystals: a materials chemist point of view
    Vivien, D
    ROMOPTO 2003: SEVENTH CONFERENCE ON OPTICS, 2004, 5581 : 56 - 64
  • [9] Plant sources of propolis: an update from a chemist's point of view
    Bankova, Vassya
    Popova, Milena
    Trusheva, Boryana
    NATURAL PRODUCT COMMUNICATIONS, 2006, 1 (11) : 1023 - 1028
  • [10] Second-generation de novo design: a view from a medicinal chemist perspective
    Zaliani, Andrea
    Boda, Krisztina
    Seidel, Thomas
    Herwig, Achim
    Schwab, Christof H.
    Gasteiger, Johann
    Claussen, Holger
    Lemmen, Christian
    Degen, Joerg
    Paern, Juri
    Rarey, Matthias
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2009, 23 (08) : 593 - 602